Expert central reading services: ensuring the success of your clinical trials.
- Expert advice on study design and imaging protocols
- Provision of site-specific MRI technical manuals
- Compliant and secure web-portal scan upload facility
Dummy-run and Site Certification
- Site collaboration and support to ensure MRI exam success
- Site certification upon approved dummy run
- Harmonisation of MRI protocols across sites
- Quality inspection and routine tracking of all subject scans
- Professional and fast communication with sites and sponsor
- Secure and compliant record-keeping practices
- Data analysis and archiving
- Routine progress reporting to the Sponsor
- Timely and accurate reporting of final datasets to statistical vendors and Sponsors
- Reproducibility and traceability of data to all sources
- Commitment to the highest standards and ethics
- Strict adherence to standards of applicable regulatory standards
- Certified internal QMS and audit system
- Cooperation with any external and/or health authority regulatory audits
The SNAC toolbox –standardised and custom outcome measures for clinical trials and remyelination studies.
SNAC offers a standardised selection of lesion activity and brain volumetric outcome measures, along with customised solutions for studies utilising advanced imaging techniques such as diffusion imaging and magnetisation transfer imaging. We have also developed a turn-key, multimodal central reading solution for Phase 2 clinical trials of emerging remyelinating therapies. This incorporates regulatory-compliant central reading for MRI, multifocal visual evoked potential (mfVEP) and optical coherence tomography (OCT).
Advanced imaging techniques and analysis.
SNAC’s advanced imaging analytics platform quantifies tissue injury and microstructural changes within MS lesions and surrounding white matter.
Conventional MRI approaches (e.g. fluid-attenuated inversion recovery (FLAIR), T1-weighted imaging) are limited and unable to reliably differentiate between lesion pathologies such as demyelination, inflammation, gliosis and remyelination. SNAC routinely employs advanced MRI techniques (such as MTR and diffusion imaging) to increase the specificity and sensitivity for particular tissue components, such as myelin, providing an avenue for the assessment of repair processes such as remyelination.
A multimodal turnkey central reading solution for Phase 2 remyelination clinical trials.
SNAC is redefining Phase 2 clinical trials of emerging remyelinating therapies for MS. We offer a unique, multimodal approach for testing remyelination in both acute and chronic MS lesions. Specifically, we utilise the visual system as a platform to provide accurate measures of remyelination that have been validated with both clinical research and Phase 2 clinical trials. The visual pathways are highly susceptible to damage in MS; and are accessible to in-vivo structural and functional measurements, including Multifocal Visual Evoked Potential (mfVEP), Magnetic Resonance Imaging (MRI), Optical Coherence Tomography (OCT), and Low Contrast Visual Acuity (LCVA).Watch Video
Discover Other Services at SNAC
Clinical trials for other diseases
SNAC also provide central MRI and CT reading for clinical trials involving other neurological diseases apart from MS. This includes dedicated services for cerebrovascular and neurodegenerative disease treatment clinical trials.
Collaborate with us
In addition, SNAC run central MRI reading for independent and collaborative clinical research and Investigator Initiated Studies, including studies involving predictive modelling of patient outcomes and extended monitoring of existing therapies. The results of these studies support an improved understanding of drug effects and their applications, plus enhanced clinical practice and patient care. At SNAC, we offer a full suite of regulatory-compliant imaging-related services tailored to meet your clinical trial needs. With a particular focus on MS clinical trials, our central MRI reading service is your solution to investigate the efficacy of disease-modifying therapies.